Date:	8/9/2023
Your Name:	Aïda Fall
Manuscript Title:	Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms.
Manuscript Number (if known):	DADM-D-23-00122

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or 	☑ None Time frame: past 36 month ☑ None	Click the tab key to add additional rows.	
	contracts from any entity (if not indicated in item #1 above).		
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None 	
7	Support for attending meetings and/or travel	[⊠] None [
8	Patents planned, issued or pending	[⊠] None 	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None [
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: [[x]] I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	8/25/2023
Your Name:	Peter Fischer
Manuscript Title:	Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms.
Manuscript Number (if known):	DADM-D-23-00122

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	g of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	□ □ <t< th=""><th>Click the tab key to add additional rows.</th></t<>	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None 	
7	Support for attending meetings and/or travel	[⊠] None [
8	Patents planned, issued or pending	[⊠] None 	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None [
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: [[x]] I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	8/22/2023	
Your Name:	Prof. Dr. Peter Riederer	
Manuscript Title:	Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms.	
Manuscript Number (if known):	DADM-D-23-00122	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	g of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	□ □ <t< th=""><th>Click the tab key to add additional rows.</th></t<>	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None 	
7	Support for attending meetings and/or travel	[⊠] None [
8	Patents planned, issued or pending	[⊠] None 	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None [
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Please place an "X" next to the following statement to indicate your agreement: [[x]] I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	8/22/2023	
Your Name: Sonja Maria Kagerer		
Manuscript Title:	Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms.	
Manuscript Number (if known):	DADM-D-23-00122	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Synapsis Alzheimer Research Switzerland	Grant No 2018-PI06, Main Applicant: Prof. P. G. Unschuld, Payment to University of Zurich/University of Geneva Click the tab key to add additional rows.
		Time frame: past 36 month	IS
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None 	
7	Support for attending meetings and/or travel	[⊠] None [
8	Patents planned, issued or pending	[⊠] None 	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None [
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Please place an "X" next to the following statement to indicate your agreement: [I] I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	8/9/2023	
Your Name: Susanne Walitza		
Manuscript Title:	Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms.	
Manuscript Number (if known):	DADM-D-23-00122	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing	 None EADB study (https://www.neurodegenerationresearch.eu/s urvey/eadb-a-european-dna-bank-for- deciphering-the-missing-heritability-of- alzheimer%C2%92s-disease/) supported by 	Supported the GWAS analysis
	charges, etc.)	JPND	
	No time limit for this item.		Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from	[□] None	
	any entity (if not indicated in item #1 above).	EU H2022: Boosting Societal Adaptation and Mental Health in a Rapidly Digitalizing, Post- Pandemic Europe (BOOTSTRAP); PI of the Project Recruitment	
		Swiss National Foundation, Scientific Exchanges: WASAD Congress 2023 – Dealing with stress and anxiety in a world of chronic crises; PI	
		Heuberg Foundation: Clinical Zurich Youth Suicide Prevention Project	
		University Medical Center Groningen (UMCG) – Collaborative Project: multi-centre study Collaborative Genomic Studies of Tourette Disorder (Tic Genetics)	

Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
Uniscientia Foundation: Die psychischen		
Auswirkungen der Covid-19-Pandemie auf Kinder		
und Jugendliche, ihre Eltern sowie auf junge		
Erwachsene in der Schweiz; Teil 2 (The		
psychological impact of the Covid 19 pandemic on		
children and adolescents, their parents, and		
young adults in Switzerland; second wave)		
Projekt «AdoASSIP – Prävention von		
Suizidversuchen und Suiziden bei Adoleszenten»		
GFCH (gesundheitsfoerderung.ch)		
Swiss State Secretariat for Education, Research		
and Innovation (SERI) & University of Geneva,		
Research Preparation Grants (RPG) with Russia		
2020: Impact of genetic deficiency in the		
synthesis of brain-specific gangliosides and		
glycoproteins mediated by the ST3GAL3 and		
ST3GAL5 genes on the neuropathology		
Uniscientia Foundation: Die psychischen		1
Auswirkungen der Covid-19-Pandemie auf Kinder		
und Jugendliche, ihre Eltern sowie auf junge		
Erwachsene in der Schweiz (The psychological		
impact of the Covid 19 pandemic on children and		
adolescents, their parents, and young adults in		
Switzerland);		
UZH Foundation & Erika Schwarz Foundation: The		
psychological impact of the coronavirus pandemic		
shutdown in Switzerland		
Vontobel Foundation: Add-on to the SNF project		
"Omega-3 fatty acids as first-line treatment in		
Paediatric Depression. A 36-week, multi-centre,		
double-blind, placebo-controlled randomized		
superiority study. Add-on for funding a doctoral		
fellowship		
Ebnet Foundation: Add-on to the SNF project		
"Omega-3 fatty acids as first-line treatment in		
Paediatric Depression. A 36-week, multi-centre,		
double-blind, placebo-controlled randomized		
superiority study. Add-on for funding a doctoral		
fellowship		
Oxford - Brain @McGill - ZNZ Partnership in the		
Neurosciences (Oxford, McGill University and		
Neuroscience Center Zurich, University of Zurich		
& ETH), Collaborative Project: Epigenetics and		
ADHD: Family-based and case-control association		
studies of the dopamine and serotonin		
transporter gene;		
COST (European Cooperation in Science and		
Technology): CA16207 – European Network for		
Problematic Usage of the Internet (EU-PUI)		
Gertrud Thalmann Fonds of the UPK Basel,		1
Collaborative Project: Effects of Omega-3 fatty		
acids supplementation on sleep and physical		
activity in pediatric depression. Add-on study to		
the investigator-initiated clinical trial SNF project		
		}

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Omega-3 fatty acids as first-line treatment in Pediatric Depression. A 36-week, multi-centre, double-blind, placebo-controlled randomized superiority study		
		Swiss National Foundation, Investigator Initiated Clinical Trial: Omega-3 fatty acids as first-line treatment in Paediatric Depression. A 36-week, multi-centre, double-blind, placebo-controlled randomized superiority study		
		University Medical Center Utrecht & Stanley Medical Research Institute – Collaborative Project: multi-centre study Placebo-controlled trial in subjects at Ultra-high Risk for Psychosis with Omega-3 fatty acids in Europe (PURPOSE)		
		BfArM: Pharmakovigilanz in der Psychiatrie / Neurologie: Pharmakovigilanz bei Patienten im Kindes- und Jugendalter (Kompetenznetz TDM KJP e.V.): Erhebung von Beobachtungsdaten zu Wirkung, Neben-und Wechselwirkungen von (Off-		
		Label-) verordneten Antidepressiva und Antipsychotika sowie Untersuchungen zu arzneimittelbedingten Risiken von Psychostimulanzien bei der hyperkinetischen Störung		
		Olga Mayenfisch Foundation: Identification of biomarkers for obsessive-compulsive disorder in children and adolescents		
3	Royalties or licenses	[□] None		
		Georg Thieme Verlag KG Stuttgart, New York	Payment to Susanne Walitza	
		Hogrefe Publishing Group	Payment to Susanne Walitza	
		Kohlhammer Publishing	Payment to Susanne Walitza	
		Springer Berlin, Heidelberg	Payment to Susanne Walitza	_
		Beltz publishing group	Payment to Susanne Walitza	
4	Consulting fees	⊠ None		
5	Payment or Difference			
	lectures, presentations, speakers bureaus, manuscript writing or	Education Weiterbildungsverein Deutschschweizer Kliniken	Payment to Susanne Walitza	
	educational events			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
6	Payment for expert testimony	[⊠] None [
7	Support for attending meetings and/or travel	[⊠] None 	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None 	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	 None President of the IPKJ Psychotherapy Institute Board Member Schweizerischer Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie Chair of ICOCS, Board Member ZNZ, SGZ Board Member SGAD 	Payment to Susanne Walitza Payment to Susanne Walitza NO Payments Payment to Susanne Walitza
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None [

Name all entities with whom you have this relationship or indicate none (add rows as needed)Specifications/Comments (e.g., if payments were made to you or to your institution)

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	8/14/2023	
Your Name: Aleksandra Maleska Maceski		
Manuscript Title:	Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms.	
Manuscript Number (if known):	DADM-D-23-00122	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you relationship or indicate none (add		Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since	the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		me: past 36 month	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None		
3	Royalties or licenses	None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None 	
7	Support for attending meetings and/or travel	[⊠] None [
8	Patents planned, issued or pending	[⊠] None 	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None [
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement:		

Date:	8/13/2023
Your Name:	Edna Grünblatt
Manuscript Title:	Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms.
Manuscript Number (if known):	DADM-D-23-00122

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	□ None [VITA-Study: Ludwig Boltzmann Institute of Aging Research Vienna, Austria EADB study (https://www.neurodegenerationresearch.eu/s urvey/eadb-a-european-dna-bank-for- deciphering-the-missing-heritability-of- alzheimer%C2%92s-disease/) supported by JPND Time frame: past 36 month [X] None	Supported the VITA study recruitment Supported the GWAS analysis Click the tab key to add additional rows.
3	#1 above). Royalties or licenses	⊠ None	
	licenses		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None 	
7	Support for attending meetings and/or travel	[⊠] None [
8	Patents planned, issued or pending	[⊠] None 	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None [
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None 	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None 	
13	Other financial or non-financial interests	[⊠] None [
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: [I] I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: September 4, 2023 Your Name: Jens Kuhle Manuscript Title: Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms. Manuscript number (if known): DADM D. 22, 00122

Manuscript number (if known): DADM-D-23-00122

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None Progressive MS Alliance Celgene Novartis Roche Magele	Institution Institution Institution Institution
		Merck	Institution
		Swiss National Research Foundation (320030_189140/1)	Institution
З	Royalties or licenses	XNone	

4	Consulting fees	None	
4	consulting lees		Institution
		Biogen	
		Quanterix	Institution
			Institution
		Stata DX	Institution
		Alnylam	Institution
		Bristol Myers Squibb	Institution
		Merck	Institution
		NeuroGenesis	Institution
		Novartis	Institution
		Roche	Institution
		Stata DX	Institution
5	Payment or honoraria for	None	
	lectures, presentations,	Biogen	Institution
	speakers bureaus, manuscript writing or	Novartis	Institution
	educational events		
		Roche	Institution
6	Payment for expert	XNone	
	testimony		
7	Support for attending	_XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
0	pending		
	pending		
0		NI	
9	Participation on a Data	None	
	Safety Monitoring Board or	Biogen	Institution
	Advisory Board	Merck	Institution
		Novartis	Institution
		Roche	Institution
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

Please place an "X" next to the following statement to indicate your agreement:

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	9/4/2023
Your Name:	Pascal Benkert
Manuscript Title:	Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms.
Manuscript Number (if known):	DADM-D-23-00122

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	g of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Image: State of the st	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	☑ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None 	
7	Support for attending meetings and/or travel	[⊠] None 	
8	Patents planned, issued or pending	[⊠] None 	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None [
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: Icertify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	8/21/2023	
Your Name:	Paul Gerson Unschuld	
Manuscript Title:	Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms.	
Manuscript Number (if known):	DADM-D-23-00122	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Synapsis Alzheimer Research Switzerland Synapsis Alzheimer Research Switzerland Time frame: past 36 month	Grant No 2018-PI06, Main Applicant: Prof. P. G. Unschuld, Payment to University of Zurich/University of Geneva Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None 	
7	Support for attending meetings and/or travel	[⊠] None [
8	Patents planned, issued or pending	[⊠] None 	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None [
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None 	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None [
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: [\Box] I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	8/22/2023	
Your Name:	Swapnil Awasthi	
Manuscript Title:	Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset ofclinical symptoms.	
Manuscript Number (if known):	DADM-D-23-00122	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	g of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☑ None Time frame: past 36 mont	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	☑ None ☑	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None 	
7	Support for attending meetings and/or travel	[⊠] None [
8	Patents planned, issued or pending	[⊠] None 	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None [
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: [\vec{A}] I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	9/23/2023
Your Name:	Stephan Ripke
Manuscript Title:	Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms.
Manuscript Number (if known):	DADM-D-23-00122

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not	☑ None ☑ Image: past 36 month ☑ None	Click the tab key to add additional rows.
3	indicated in item #1 above). Royalties or	⊠ None	
	licenses		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None 	
7	Support for attending meetings and/or travel	[⊠] None 	
8	Patents planned, issued or pending	[⊠] None 	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None [
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: [\Box] I certify that I have answered every question and have not altered the wording of any of the questions on this form.		